$3.80
+0.23 (+6.44%)
Open$3.61
Previous Close$3.57
Day High$3.83
Day Low$3.58
52W High$36.17
52W Low$13.74
Volume—
Avg Volume358.1K
Market Cap91.47M
P/E Ratio—
EPS$-0.33
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+707.6% upside
Current
$3.80
$3.80
Target
$30.69
$30.69
$21.79
$30.69 avg
$37.55
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.36M | 15.69M | 16.28M |
| Net Income | 427.8K | 557.5K | 468.9K |
| Profit Margin | 2.8% | 3.6% | 2.9% |
| EBITDA | 737.1K | 726.6K | 787.3K |
| Free Cash Flow | 462.7K | 441.5K | 603.2K |
| Rev Growth | -9.8% | -7.6% | +22.3% |
| Debt/Equity | 0.33 | 0.41 | 0.42 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |